The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer

Endocrine-Related Cancer

Volumn 21, Issue 5, 2014, Pages R395-R407

  Ta, Huy Q ^a   Gioeli, Daniel ^a,b  

^a and Cancer Biology ^*  (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Androgen receptor; Cell signaling; Chemotherapy; Endocrine therapy resistance; Oncogene

Indexed keywords

ANDROGEN RECEPTOR; AR PROTEIN, HUMAN;

CELL CYCLE CHECKPOINT; DNA DAMAGE; HUMAN; MALE; METABOLISM; PROSTATE TUMOR; SIGNAL TRANSDUCTION;

CELL CYCLE CHECKPOINTS; DNA DAMAGE; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 84907535087     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0217     Document Type: Review

References (97)

1. Aguilera A & Gómez-González B 2008 Genome instability: a mechanistic view of its causes and consequences. Nature Reviews. Genetics 9 204-217. (doi:10.1038/nrg2268)
2. Ahman AK, Jonsson BA, Damber JE, Bergh A & Grönberg H 2001 Low frequency of microsatellite instability in hereditary prostate cancer. BJU International 87 334-338. (doi:10.1046/j.1464-410x.2001.00104.x)
3. Al-Ubaidi FL, Schultz N, Loseva O, Egevad L, Granfors T & Helleday T 2013 Castration therapy results in decreased Ku70 levels in prostate cancer. Clinical Cancer Research 19 1547-1556. (doi:10.1158/1078-0432.CCR-12-2795)
4. Angèle S, Falconer A, Edwards SM, Dörk T, Bremer M, Moullan N, Chapot B, Muir K, Houlston R, Norman AR et al. 2004 ATM polymorphisms as risk factors for prostate cancer development. British Journal of Cancer 91783-787. (doi:10.1038/sj.bjc.6602007)
5. Bai S & Wilson EM 2008 Epidermal-growth-factor-dependent phosphorylation and ubiquitinylation of MAGE-11 regulates its interaction with-the androgen receptor. Molecular and Cellular Biology 28 1947-1963.(doi:10.1128/MCB.01672-07)
6. Balk SP 2002 Androgen receptor as a target in androgen-independent prostate cancer. Urology 60 (3 Suppl 1) 132-138 discussion 138-139. (doi:10.1016/S0090-4295(02)01593-5)
7. Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K et al. 2014 Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT Study. European Urology 66489-499. (doi:10.1016/j.eururo.2014.01.003)
8. Bartek J & Lukas J 2003 Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3 421-429. (doi:10.1016/S1535-6108(03)00110-7)
9. Bartek J, Bartkova J & Lukas J 2007 DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 26 7773-7779. (doi:10.1038/sj.onc.1210881)
10. Bartkova J, Guldberg P, Gronbaek K, Koed K, Primdahl H, Moller K, Lukas J, Orntoft TF & Bartek J 2004 Aberrations of the Chk2 tumour suppressor in advanced urinary bladder cancer. Oncogene 23 8545-8551.(doi:10.1038/sj.onc.1207878)
11. Bastus NC, Boyd LK, Mao X, Stankiewicz E, Kudahetti SC, Oliver RT, Berney DM & Lu YJ 2010 Androgen-induced TMPRSS2: ERG fusion in nonmalignant prostate epithelial cells. Cancer Research 70 9544-9548.(doi:10.1158/0008-5472.CAN-10-1638)
12. Boboila C, Yan C, Wesemann DR, Jankovic M, Wang JH, Manis J, Nussenzweig A, Nussenzweig M & Alt FW 2010 Alternative end-joining catalyzes class switch recombination in the absence of both Ku70 and DNA ligase 4. Journal of Experimental Medicine 207 417-427. (doi:10.1084/jem.20092449)
13. Boboila C, Alt FW & Schwer B 2012 Classical and alternative end-joining pathways for repair of lymphocyte-specific and general DNA double-strand breaks. Advances in Immunology 116 1-49. (doi:10.1016/B978-0-12-394300-2.00001-6)
14. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Billiet I et al. 2010 External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncology 11 1066-1073. (doi:10.1016/S1470-2045(10)70223-0)
15. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J et al. 2011 Mechanistic rationale for inhibition of poly (ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19 664-678. (doi:10.1016/j.ccr.2011.04.010)
16. Chen Y, Wang J, Fraig MM, Metcalf J, Turner WR, Bissada NK, Watson DK & Schweinfest CW 2001 Defects of DNA mismatch repair in human prostate cancer. Cancer Research 61 4112-4121.
17. Chen L, Elahi A, Pow-Sang J, Lazarus P & Park J 2003a Association between polymorphism of human oxoguanine glycosylase 1 and risk of prostate cancer. Journal of Urology 170 2471-2474. (doi:10.1097/01.ju.0000087498.23008.bb)
18. Chen Y, Wang J, Fraig MM, Henderson K, Bissada NK, Watson DK & Schweinfest CW 2003b Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer. International Journal of Oncology 22 1033-1043. (doi:10.3892/ijo.22.5.1033)
19. Chiu Y-T, Liu J, Tang K, Wong Y-C, Khanna KK & Ling M-T 2012 Inactivation of ATM/ATR DNA damage checkpoint promotes androgen induced chromosomal instability in prostate epithelial cells. PLoS ONE7 e51108. (doi:10.1371/journal.pone.0051108)
20. Ciccia A & Elledge SJ 2010 The DNA damage response: making it safe toplay with knives. Molecular Cell 40 179-204. (doi:10.1016/j.molcel.2010.09.019)
21. Culig Z & Bartsch G 2006 Androgen axis in prostate cancer. Journal of Cellular Biochemistry 99 373-381. (doi:10.1002/jcb.20898)
22. Cybulski C, Huzarski T, Górski B, Masojć B, Mierzejewski M, Debniak T, Gliniewicz B, Matyjasik J, Złowocka E, Kurzawski G et al. 2004 A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Research 64 2677-2679. (doi:10.1158/0008-5472.CAN-04-0341)
23. Cybulski C, Wokołorczyk D, Kładny J, Kurzawski G, Suchy J, Grabowska E, Gronwald J, Huzarski T, Byrski T, Górski B et al. 2007 Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations? European Journal of Human Genetics 15 237-241. (doi:10.1038/sj.ejhg.5201734)
24. Dahiya R, Lee C, McCarville J, Hu W, Kaur G & Deng G 1997 High frequency of genetic instability of microsatellites in human prostatic adenocarcinoma. International Journal of Cancer. Journal International du Cancer 72 762-767. (doi:10.1002/(SICI)1097-0215(19970904)72:5!762::AID-IJC10O3.0.CO;2-B)
25. Deriano L & Roth DB 2013 Modernizing the nonhomologous end-joining repertoire: alternative and classical NHEJ share the stage. Annual Review of Genetics 47 433-455. (doi:10.1146/annurev-genet-110711-155540)
26. Deriano L, Stracker TH, Baker A, Petrini JH & Roth DB 2009 Roles for NBS1 in alternative nonhomologous end-joining of V(D)J recombination intermediates. Molecular Cell 34 13-25. (doi:10.1016/j.molcel.2009.03.009)
27. Dong X, Wang L, Taniguchi K, Wang X, Cunningham JM, McDonnell SK, Qian C, Marks AF, Slager SL, Peterson BJ et al. 2003 Mutations in CHEK2 associated with prostate cancer risk. American Journal Human Genetics72 270-280. (doi:10.1086/346094)
28. El-Khamisy SF, Masutani M, Suzuki H & Caldecott KW 2003 A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Research 31 5526-5533.(doi:10.1093/nar/gkg761)
29. Evans RM 1988 The steroid and thyroid hormone receptor superfamily. Science 240 889-895. (doi:10.1126/science.3283939)
30. Falck J 2001 Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway. Published online: 06 September 2001; | doi:10.1038/sj.onc.1204811, 20(39). Available at: http://www.nature.com/onc/journal/v20/n39/full/1204811a.html [Accessed April 2, 2014].
31. Fan R, Kumaravel TS, Jalali F, Marrano P, Squire JA & Bristow RG 2004 Defective DNA strand break repair after DNA damage in prostate cancer cells implications for genetic instability and prostate cancer progression. Cancer Research 64 8526-8533. (doi:10.1158/0008-5472.CAN-04-1601)
32. Feldman BJ & Feldman D 2001 The development of androgen-independent prostate cancer. Nature Reviews. Cancer 1 34-45. (doi:10.1038/35094009)
33. Gelmann EP 2002 Molecular biology of the androgen receptor. Journal of Clinical Oncology 20 3001-3015. (doi:10.1200/JCO.2002.10.018)
34. van Gils CH, Bostick RM, Stern MC & Taylor JA 2002 Differences in base excision repair capacity may modulate the effect of dietary antioxidant intake on prostate cancer risk: an example of polymorphisms in the XRCC1 gene. Cancer Epidemiology Biomarkers & Prevention 111279-1284.
35. Goodwin JF et al. 2013. A hormone-DNA repair circuit governs the response to genotoxic Insult. Cancer Discovery. Available at: http://cancerdiscovery.aacrjournals.org/content/early/2013/10/17/2159-8290.CD-13-0108 [Accessed October 24, 2013].
36. Guirouilh-Barbat J, Rass E, Plo I, Bertrand P & Lopez BS 2007 Defects in XRCC4 and KU80 differentially affect the joining of distal nonhomologous ends. PNAS 104 20902-20907. (doi:10.1073/pnas.0708541104)
37. Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, Isaacs WB, Bova GS, Liu W, Xu J et al. 2010 Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nature Genetics 42 668-675. (doi:10.1038/ng.613)
38. Haffner MC, De Marzo AM, Meeker AK, Nelson WG & Yegnasubramanian S 2011 Transcription-induced DNA double strand breaks: both oncogenic force and potential therapeutic target? Clinical Cancer Research 17 3858-3864. (doi:10.1158/1078-0432.CCR-10-2044)
39. Haince JF, McDonald D, Rodrigue A, Déry U, Masson JY, Hendzel MJ & Poirier GG 2008 PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites. Journal of Biological Chemistry 283 1197-1208. (doi:10.1074/jbc.M706734200)
40. Hanahan D & Weinberg RA 2011 Hallmarks of cancer: the next generation. Cell 144 646-674. (doi:10.1016/j.cell.2011.02.013.
41. Haruki N, Saito H, Tatematsu Y, Konishi H, Harano T, Masuda A, Osada H, Fujii Y & Takahashi T 2000 Histological type-selective, tumor-predominant expression of a novel CHK1 isoform and infrequentin vivo somatic CHK2 mutation in small cell lung cancer. Cancer Research 60 4689-4692.
42. Heinlein CA & Chang C 2002 Androgen receptor (AR) coregulators: an overview. Endocrine Reviews 23 175-200. (doi:10.1210/edrv.23.2.0460)
43. Hess-Wilson JK, Daly HK, Zagorski WA, Montville CP & Knudsen KE 2006 Mitogenic action of the androgen receptor sensitizes prostate cancer cells to taxane-based cytotoxic insult. Cancer Research 66 11998-12008. (doi:10.1158/0008-5472.CAN-06-2249)
44. Hickey TE, Robinson JL, Carroll JS & Tilley WD 2012 Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Molecular Endocrinology 26 1252-1267. (doi:10.1210/me.2012-1107)
45. Hoeijmakers JH 2009 DNA damage, aging, and cancer. New England Journal of Medicine 361 1475-1485. (doi:10.1056/NEJMra0804615)
46. Ide H, Lu Y, Yu J, China T, Kumamoto T, Koseki T, Yamaguchi R, Muto S & Horie S 2012 Testosterone promotes DNA damage response under oxidative stress in prostate cancer cell lines. Prostate 72 1407-1411.(doi:10.1002/pros.22492)
47. Jenster G 1999 The role of the androgen receptor in the development and progression of prostate cancer. Seminars in Oncology 26 407-421.
48. Ju BG, Lunyak VV, Perissi V, Garcia-Bassets I, Rose DW, Glass CK & Rosenfeld MG 2006 A topoisomerase IIb-mediated dsDNA break required for regulated transcription. Science 312 1798-1802. (doi:10.1126/science.1127196)
49. Koontz BF & Lee WR 2011 External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation. Archivos Españoles de Urología 64 858-864.
50. Li J, Williams BL, Haire LF, Goldberg M, Wilker E, Durocher D, Yaffe MB, Jackson SP & Smerdon SJ 2002 Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2. Molecular Cell 9 1045-1054. (doi:10.1016/S1097-2765(02)00527-0)
51. Li D, Kumaraswamy E, Harlan-Williams LM & Jensen RA 2013 The role of BRCA1 and BRCA2 in prostate cancer. Frontiers in Bioscience 18 1445-1459. (doi:10.2741/4191)
52. Lin C, Yang L, Tanasa B, Hutt K, Ju BG, Ohgi K, Zhang J, Rose DW, Fu XD, Glass CK et al. 2009 Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 139 1069-1083. (doi:10.1016/j.cell.2009.11.030)
53. Litvinov IV, Antony L, Dalrymple SL, Becker R, Cheng L & Isaacs JT 2006 PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor. Prostate 66 1329-1338. (doi:10.1002/pros.20483)
54. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P et al. 1995 The nuclearreceptor superfamily: the second decade. Cell 83 835-839. (doi:10.1016/0092-8674(95)90199-X)
55. Manke IA, Nguyen A, Lim D, Stewart MQ, Elia AE & Yaffe MB 2005 MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Molecular Cell 17 37-48. (doi:10.1016/j.molcel.2004.11.021)
56. Mantoni TS, Reid G & Garrett MD 2006 Androgen receptor activity is inhibited in response to genotoxic agents in a p53-independent manner. Oncogene 25 3139-3149. (doi:10.1038/sj.onc.1209347)
57. Martin L, Coffey M, Lawler M, Hollywood D & Marignol L 2010 DNA mismatch repair and the transition to hormone independence in breast and prostate cancer. Cancer Letters 291 142-149. (doi:10.1016/j.canlet.2009.10.007)
58. Matsuoka S, Nakagawa T, Masuda A, Haruki N, Elledge SJ & Takahashi T 2001 Reduced expression and impaired kinase activity of a Chk2 mutant identified in human lung cancer. Cancer Research 61 5362-5365.
59. Mayeur GL, Kung WJ, Martinez A, Izumiya C, Chen DJ & Kung HJ 2005 Ku is a novel transcriptional recycling coactivator of the androgen receptor in prostate cancer cells. Journal of Biological Chemistry 280 10827-10833. (doi:10.1074/jbc.M413336200)
60. Miller CW, Ikezoe T, Krug U, Hofmann WK, Tavor S, Vegesna V, Tsukasaki K, Takeuchi S & Koeffler HP 2002 Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors. Genes, Chromosomes & Cancer 33 17-21. (doi:10.1002/gcc.1207)
61. Mills IG 2014 Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. Nature Reviews. Cancer 14 187-198. (doi:10.1038/nrc3678)
62. Nevanlinna H & Bartek J 2006 The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 25 5912-5919. (doi:10.1038/sj.onc.1209877)
63. Park JJ, Irvine RA, Buchanan G, Koh SS, Park JM, Tilley WD, Stallcup MR, Press MF & Coetzee GA 2000 Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. Cancer Research 60 5946-5949.
64. Polkinghorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ, Arora VK, Yen WF, Cai L, Zheng D et al. 2013 Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discovery 3 1245-1253.(doi:10.1158/2159-8290.CD-13-0172)
65. Ponguta LA, Gregory CW, French FS & Wilson EM 2008 Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer. Journal of Biological Chemistry 283 20989-21001. (doi:10.1074/jbc.M802392200)
66. van Puijenbroek M, van Asperen CJ, van Mil A, Devilee P, van Wezel T & Morreau H 2005 Homozygosity for a CHEK2∗1100delC mutation identified in familial colorectal cancer does not lead to a severe clinical phenotype. Journal of Pathology 206 198-204. (doi:10.1002/path.1764)
67. Rass E, Grabarz A, Plo I, Gautier J, Bertrand P & Lopez BS 2009 Role of Mre11 in chromosomal nonhomologous end joining in mammalian cells. Nature Structural & Molecular Biology 16 819-824. (doi:10.1038/nsmb.1641)
68. Reddy A, Yuille M, Sullivan A, Repellin C, Bell A, Tidy JA, Evans DJ, Farrell PJ, Gusterson B & Gasco M 2002 Analysis of CHK2 in vulval neoplasia. British Journal of Cancer 86 756-760. (doi:10.1038/sj.bjc.6600131)
69. Reinhardt HC & Yaffe MB 2009 Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Current Opinion in Cell Biology 21 245-255. (doi:10.1016/j.ceb.2009.01.018)
70. Rybicki BA, Conti DV, Moreira A, Cicek M, Casey G & Witte JS 2004 DNA repair gene XRCC1 and XPD polymorphisms and risk of prostate cancer. Cancer Epidemiology Biomarkers & Prevention 13 23-29. (doi:10.1158/1055-9965.EPI-03-0053)
71. Schayek H, Haugk K, Sun S, True LD, Plymate SR & Werner H 2009 Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner. Clinical Cancer Research 15 1558-1565. (doi:10.1158/1078-0432.CCR-08-1440)
72. Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, Liu F, Planck JL, Ravindranathan P, Chinnaiyan AM et al. 2012 Dual roles of PARP-1 promote cancer growth and progression. Cancer Discovery 2 1134-1149. (doi:10.1158/2159-8290.CD-12-0120)
73. Sfeir A & de Lange T 2012 Removal of shelterin reveals the telomere end-protection problem. Science 336 593-597. (doi:10.1126/science.1218498)
74. Shin S & Verma IM 2003 BRCA2 cooperates with histone acetyltransferases in androgen receptor-mediated transcription. PNAS 100 7201-7206.(doi:10.1073/pnas.1132020100)
75. Simsek D & Jasin M 2010 Alternative end-joining is suppressed by the canonical NHEJ component Xrcc4-ligase IV during chromosomal translocation formation. Nature Structural & Molecular Biology 17 410-416. (doi:10.1038/nsmb.1773)
76. Sirbu BM & Cortez D 2013 DNA damage response: three levels of DNA repair regulation. Cold Spring Harbor Perspectives in Biology 5 a012724.(doi:10.1101/cshperspect.a012724)
77. Smith J et al. 2010 Chapter 3 - The ATM-Chk2 and ATR-Chk1 Pathways in DNA Damage Signaling and Cancer. In Advances in Cancer Research. Academic Press, pp 73-112. Available at: http://www.sciencedirect.com/science/article/pii/B9780123808882000030 [Accessed May 22, 2012].
78. Smits VA, Warmerdam DO, Martin Y & Freire R 2010 Mechanisms of ATR-mediated checkpoint signalling. Frontiers in Bioscience 15 840-853. (doi:10.2741/3649)
79. Tamura RE, de Vasconcellos JF, Sarkar D, Libermann TA, Fisher PB & Zerbini LF 2012 GADD45 proteins: central players in tumorigenesis. Current Molecular Medicine 12 634-651. (doi:10.2174/156652412800619978)
80. Tort F, Hernàndez S, Beà S, Martínez A, Esteller M, Herman JG, Puig X, Camacho E, Sańchez M, Nayach I et al. 2002 CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. Blood 100 4602-4608. (doi:10.1182/blood-2002-04-1078)
81. Vogelstein B, Lane D & Levine AJ 2000 Surfing the p53 network. Nature 408307-310. (doi:10.1038/35042675)
82. Vousden KH & Lu X 2002 Live or let die: the cell's response to p53. Nature Reviews. Cancer 2 594-604. (doi:10.1038/nrc864)
83. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S et al. 2006 Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. Journal of the American Medical Association 295 1379-1388. (doi:10.1001/jama.295.12.1379)
84. Wang L, Hsu CL, Ni J, Wang PH, Yeh S, Keng P & Chang C 2004 Human checkpoint protein hRad9 functions as a negative coregulator to repress androgen receptor transactivation in prostate cancer cells. Molecular and Cellular Biology 24 2202-2213. (doi:10.1128/MCB.24.5.2202-2213.2004)
85. Wang Q, Li W, Liu XS, Carroll JS, Jänne OA, Keeton EK, Chinnaiyan AM, Pienta KJ & Brown M 2007 A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Molecular Cell 27 380-392. (doi:10.1016/j.molcel.2007.05.041)
86. Williams LH, Choong D, Johnson SA & Campbell IG 2006 Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers. Clinical Cancer Research 12 6967-6972. (doi:10.1158/1078-0432.CCR-06-1770)
87. Wu X, Webster SR & Chen J 2001 Characterization of tumor-associated Chk2 mutations. Journal of Biological Chemistry 276 2971-2974. (doi:10.1074/jbc.M009727200)
88. Wu X, Geraldes P, Platt JL & Cascalho M 2005 The double-edged sword of activation-induced cytidine deaminase. Journal of Immunology 174 934-941. (doi:10.4049/jimmunol.174.2.934)
89. Xie A, Kwok A & Scully R 2009 Role of mammalian Mre11 in classical and alternative nonhomologous end joining. Nature Structural & Molecular Biology 16 814-818. (doi:10.1038/nsmb.1640)
90. Xu J, Zheng SL, Turner A, Isaacs SD, Wiley KE, Hawkins GA, Chang BL, Bleecker ER, Walsh PC, Meyers DA et al. 2002 Associations between hOGG1 sequence variants and prostate cancer susceptibility. Cancer Research 62 2253-2257.
91. Yan CT, Boboila C, Souza EK, Franco S, Hickernell TR, Murphy M, Gumaste S, Geyer M, Zarrin AA, Manis JP et al. 2007 IgH class switching and translocations use a robust non-classical end-joining pathway. Nature 449 478-482. (doi:10.1038/nature06020)
92. Yeh S, Hu YC, Rahman M, Lin HK, Hsu CL, Ting HJ, Kang HY & Chang C2000 Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. PNAS 9711256-11261. (doi:10.1073/pnas.1903538970
93. Yeh CC, Lee C & Dahiya R 2001 DNA mismatch repair enzyme activity and gene expression in prostate cancer. Biochemical and Biophysical Research Communications 285 409-413. (doi:10.1006/bbrc.2001.5187)
94. Zhang P, Wang J, Gao W, Yuan BZ, Rogers J & Reed E 2004 CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer. Molecular Cancer 3 14. (doi:10.1186/1476-4598-3-14)
95. Zhou BB & Elledge SJ 2000 The DNA damage response: putting checkpoints in perspective. Nature 408 433-439. (doi:10.1038/35044005)
96. Zhu C, Mills KD, Ferguson DO, Lee C, Manis J, Fleming J, Gao Y, Morton CC & Alt FW 2002 Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations. Cell 109 811-821. (doi:10.1016/S0092-8674(02)00770-5)
97. Zhu A, Zhang CX & Lieberman HB 2008 Rad9 has a functional role in human prostate carcinogenesis. Cancer Research 68 1267-1274. (doi:10.1158/0008-5472.CAN-07-2304)